These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 32870418)

  • 1. Clinical characteristics of systemic lupus erythematosus patients in long-term remission without treatment.
    Jakez-Ocampo J; Rodriguez-Armida M; Fragoso-Loyo H; Lima G; Llorente L; Atisha-Fregoso Y
    Clin Rheumatol; 2020 Nov; 39(11):3365-3371. PubMed ID: 32870418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonged remission in systemic lupus erythematosus.
    Urowitz MB; Feletar M; Bruce IN; Ibañez D; Gladman DD
    J Rheumatol; 2005 Aug; 32(8):1467-72. PubMed ID: 16078321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Both prolonged remission and Lupus Low Disease Activity State are associated with reduced damage accrual in systemic lupus erythematosus.
    Tsang-A-Sjoe MW; Bultink IE; Heslinga M; Voskuyl AE
    Rheumatology (Oxford); 2017 Jan; 56(1):121-128. PubMed ID: 27803306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monophasic Disease Course in Systemic Lupus Erythematosus.
    Tselios K; Gladman DD; Touma Z; Su J; Anderson N; Urowitz MB
    J Rheumatol; 2018 Aug; 45(8):1131-1135. PubMed ID: 29858240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolonged clinical remission and low disease activity statuses are associated with better quality of life in systemic lupus erythematosus.
    Poomsalood N; Narongroeknawin P; Chaiamnuay S; Asavatanabodee P; Pakchotanon R
    Lupus; 2019 Sep; 28(10):1189-1196. PubMed ID: 31307256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of Remission and Low Disease Activity State in Systemic Lupus Erythematosus: Data from a Multiethnic, Multinational Latin American Cohort.
    Ugarte-Gil MF; Wojdyla D; Pons-Estel GJ; Quintana R; Gómez-Puerta JA; Catoggio LJ; Alvarellos A; Saurit V; Borba E; Sato E; Costallat L; Da Silva NA; Iglesias-Gamarra A; Neira O; Reyes-Llerena G; Cardiel MH; Amigo MC; Acevedo-Vásquez E; Esteva-Spinetti MH; Alarcón GS; Pons-Estel BA
    J Rheumatol; 2019 Oct; 46(10):1299-1308. PubMed ID: 30824636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonged clinical remission in patients with systemic lupus erythematosus.
    Steiman AJ; Urowitz MB; Ibañez D; Papneja A; Gladman DD
    J Rheumatol; 2014 Sep; 41(9):1808-16. PubMed ID: 25086082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolonged remission in Caucasian patients with SLE: prevalence and outcomes.
    Zen M; Iaccarino L; Gatto M; Bettio S; Nalotto L; Ghirardello A; Punzi L; Doria A
    Ann Rheum Dis; 2015 Dec; 74(12):2117-22. PubMed ID: 26223434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting.
    Gatto M; Saccon F; Zen M; Regola F; Fredi M; Andreoli L; Tincani A; Urban ML; Emmi G; Ceccarelli F; Conti F; Bortoluzzi A; Govoni M; Tani C; Mosca M; Ubiali T; Gerosa M; Bozzolo E; Canti V; Cardinaletti P; Gabrielli A; Tanti G; Gremese E; De Marchi G; De Vita S; Fasano S; Ciccia F; Pazzola G; Salvarani C; Negrini S; Puppo F; Di Matteo A; De Angelis R; Orsolini G; Rossini M; Faggioli P; Laria A; Piga M; Mathieu A; Scarpato S; Rossi FW; de Paulis A; Brunetta E; Ceribelli A; Selmi C; Prete M; Racanelli V; Vacca A; Bartoloni E; Gerli R; Larosa M; Iaccarino L; Doria A
    Arthritis Rheumatol; 2020 Aug; 72(8):1314-1324. PubMed ID: 32275125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive disease control in systemic lupus erythematosus.
    Ceccarelli F; Olivieri G; Sortino A; Dominici L; Arefayne F; Celia AI; Cipriano E; Garufi C; Lapucci M; Mancuso S; Natalucci F; Orefice V; Perricone C; Pirone C; Pacucci VA; Spinelli FR; Truglia S; Alessandri C; Sciandrone M; Conti F
    Semin Arthritis Rheum; 2021 Apr; 51(2):404-408. PubMed ID: 33652293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Remission and Low Disease Activity Status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin American Lupus Cohort (GLADEL).
    Ugarte-Gil MF; Wojdyla D; Pons-Estel GJ; Catoggio LJ; Drenkard C; Sarano J; Berbotto GA; Borba EF; Sato EI; Tavares Brenol JC; Uribe O; Ramirez Gómez LA; Guibert-Toledano M; Massardo L; Cardiel MH; Silveira LH; Chacón-Diaz R; Alarcón GS; Pons-Estel BA;
    Ann Rheum Dis; 2017 Dec; 76(12):2071-2074. PubMed ID: 28939626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and laboratory characteristics in juvenile-onset systemic lupus erythematosus across age groups.
    Massias JS; Smith EMD; Al-Abadi E; Armon K; Bailey K; Ciurtin C; Davidson J; Gardner-Medwin J; Haslam K; Hawley DP; Leahy A; Leone V; McErlane F; Mewar D; Modgil G; Moots R; Pilkington C; Ramanan AV; Rangaraj S; Riley P; Sridhar A; Wilkinson N; Beresford MW; Hedrich CM
    Lupus; 2020 Apr; 29(5):474-481. PubMed ID: 32233733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Remission and Low Disease Activity Outcomes Over 10 Years in Systemic Lupus Erythematosus.
    Tselios K; Gladman DD; Touma Z; Su J; Anderson N; Urowitz MB
    Arthritis Care Res (Hoboken); 2019 Jun; 71(6):822-828. PubMed ID: 30055090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Remission and Lupus Low Disease Activity State in Damage Prevention in a United States Systemic Lupus Erythematosus Cohort.
    Petri M; Magder LS
    Arthritis Rheumatol; 2018 Nov; 70(11):1790-1795. PubMed ID: 29806142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High disease activity at baseline does not prevent a remission in patients with systemic lupus erythematosus.
    Formiga F; Moga I; Pac M; Mitjavila F; Rivera A; Pujol R
    Rheumatology (Oxford); 1999 Aug; 38(8):724-7. PubMed ID: 10501419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease course patterns in systemic lupus erythematosus.
    Tselios K; Gladman DD; Touma Z; Su J; Anderson N; Urowitz MB
    Lupus; 2019 Jan; 28(1):114-122. PubMed ID: 30526328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolonged remission is associated with a reduced risk of cardiovascular disease in patients with systemic lupus erythematosus: a GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study.
    Fasano S; Margiotta DPE; Pierro L; Navarini L; Riccardi A; Afeltra A; Valentini G
    Clin Rheumatol; 2019 Feb; 38(2):457-463. PubMed ID: 30194649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus.
    Parodis I; Johansson P; Gomez A; Soukka S; Emamikia S; Chatzidionysiou K
    Rheumatology (Oxford); 2019 Dec; 58(12):2170-2176. PubMed ID: 31157891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors associated with remission in patients with systemic lupus erythematosus: new insights into a desirable state.
    Romo-Tena J; la Garza RR; Bartnicki-Navarrete I; Alcocer-Varela J; Gómez-Martin D
    Clin Rheumatol; 2018 Nov; 37(11):3033-3042. PubMed ID: 30056524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucocorticoid withdrawal in systemic lupus erythematosus: are remission and low disease activity reliable starting points for stopping treatment? A real-life experience.
    Tani C; Elefante E; Signorini V; Zucchi D; Lorenzoni V; Carli L; Stagnaro C; Ferro F; Mosca M
    RMD Open; 2019; 5(2):e000916. PubMed ID: 31275608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.